Pope J E
University of Western Ontario, London, Canada.
Rheum Dis Clin North Am. 1996 Nov;22(4):893-907. doi: 10.1016/s0889-857x(05)70307-0.
Guidelines for the conduct of clinical trials in progressive systemic sclerosis have been recommended to determine drug efficacy better. To date, the results of disease-modifying drugs in scleroderma have been disappointing. The treatment of esophagitis has been revolutionized by omeprazole. Raynaud's phenomenon can be treated with calcium channel blockers and iloprost. Scleroderma renal crisis can be treated with aggressive blood pressure control using angiotensin converting enzyme inhibitors. The best treatment for rapidly progressive scleroderma lung is still unknown. Future treatments in scleroderma should be tested with the use of recommended guidelines.
已推荐进行系统性硬化症临床试验的指南，以更好地确定药物疗效。迄今为止，硬皮病中改善病情药物的结果令人失望。奥美拉唑彻底改变了食管炎的治疗方法。雷诺现象可用钙通道阻滞剂和伊洛前列素治疗。硬皮病肾危象可用血管紧张素转换酶抑制剂积极控制血压来治疗。快速进展性硬皮病肺部的最佳治疗方法仍不明确。硬皮病的未来治疗应按照推荐指南进行测试。
